文献速递免疫规划慢病防控与筛查卫生政策与健康促进

拉丁美洲国家女孩人乳头瘤病毒疫苗接种的成本效果:系统综述与荟萃分析

Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2022-03-31

该系统综述与荟萃分析纳入24项研究,评估拉丁美洲国家女孩HPV疫苗接种的成本效果。多数研究结论为具有成本节约性或成本效果,但不同疫苗类型、对照筛查方法、研究视角、资助来源和成本年份的ICER存在差异。

要点

  • 多数研究认为拉丁美洲女孩HPV疫苗接种具有成本节约性或成本效果。
  • 二价疫苗平均ICER为I$ 3,804,四价疫苗为I$ 640,通用HPV-16/18疫苗为I$ 358。
  • 以HPV DNA检测为对照、社会视角、非营利资助及2008年前成本的研究平均ICER较低。

核心结论

  • 多数研究结论为拉丁美洲国家女孩HPV疫苗接种具有成本节约性或成本效果,尽管模型间存在异质性。

研究设计与样本

  • 系统检索数据库及会议、卫生部和卫生技术评估办公室的文献库,共纳入24项研究。
  • 提取增量成本效果比(ICER),数据转换为国际元(I$)并膨胀至2019年值。
  • 以人均国内生产总值为阈值判断疫苗接种的成本效果。
  • 按疫苗类型、对照筛查方法(细胞学或HPV检测)、效果指标、研究视角、资助来源、成本年份和国家计算ICER的几何均值。

主要发现

  • 二价疫苗平均ICER为I$ 3,804,四价疫苗为I$ 640,通用HPV-16/18疫苗为I$ 358。
  • 以HPV DNA检测为对照的研究平均ICER为I$ 122,以细胞学为对照为I$ 1,841。
  • 社会视角研究平均ICER为I$ 235,非社会视角为I$ 1,986。
  • 非营利资助研究平均ICER为I$ 421,制药行业资助为I$ 2,676。
  • 使用2008年前成本的研究平均ICER为I$ 365,2008年及之后为I$ 1,415。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出模型间存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer is a major public health problem in Latin America. Cost-effectiveness studies help stakeholders with decisions regarding human papillomavirus (HPV) vaccination programs, one of the main prevention measures. Our objective was to synthesize the results of cost-effectiveness studies of HPV vaccination in girls, to understand factors influencing cost-effectiveness in the region. METHODS: We systematically searched databases as well as repositories from conferences, Ministries of Health and Health Technology Assessment offices. Incremental cost-effectiveness ratios (ICERs) were extracted, with data converted to international dollars (I$) and inflated to 2019 values. We used the gross domestic product per capita as threshold for judging the cost-effectiveness of vaccination. We calculated the geometric mean ICER by type of vaccine, whether screening (cytology or HPV test) was used as comparator, effectiveness measure, perspective, source of funding, year of cost, and country. RESULTS: We found 24 studies. Despite the methodological differences, most studies concluded that HPV vaccination of girls in Latin American countries was either cost-saving or cost-effective. The mean ICER was I$ 3,804 for the bivalent vaccine, I$ 640 for the quadrivalent and I$ 358 for a generic HPV-16/18 vaccine. The mean ICER was lower in the studies that used HPV DNA test instead of cytology (I$ 122 vs I$ 1,841) as comparator; used the societal perspective (I$ 235 vs. I$ 1,986); were funded by non-profit sources instead of by pharmaceutical industry (I$ 421 vs. I$ 2,676); and used costs obtained prior to 2008 (I$ 365 vs I$ 1,415). We observed great variation in the mean ICERs by effectiveness measure (I$ 402 for per disability adjusted life years, I$ 461 for life year saved, and I$ 1,795 for quality adjusted life years). CONCLUSIONS: Most studies concluded that HPV vaccination of girls in Latin America countries was cost-saving or cost-effective, despite heterogeneity between models.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tejada RA, Malagón T, Franco EL, et al. Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis. Vaccine. 2022. PMID: 35370017. doi:10.1016/j.vaccine.2022.03.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。